KUALA LUMPUR, Zenas BioPharma, a global biopharmaceutical company has announced the appointment of Orlando Oliveira as its Chief Commercial Officer.

With a career spanning nearly 25 years, Oliveira brings a wealth of experience building high-performing global commercial teams, driving revenue growth, and fostering strategic partnerships in the biotechnology and pharmaceutical industry.

‘As we continue to advance multiple mid- to late-stage clinical development programmes, we are thrilled to welcome Orlando to the Zenas leadership team.

‘We will benefit immensely from Orlando’s broad commercial knowledge and leadership as Zenas evolves to become an integrated development and commercial biopharmaceutical company,’ said its President and Chief Operating Officer, Joe Farmer in a statement.

Meanwhile, Oliveira said he is eager to join the seasoned executive team Zenas has built, guided by their mission to deliver transformative immunology-based therapies to patients in need.

‘I look forward to working with t
his team to further develop and execute the strategies and plans for the eventual commercialisation of obexelimab and to establish Zenas as a leading global immunology-based development and commercial company,’ added Oliveira.

Prior to joining Zenas, Oliveira served as Senior Vice President and Head of International at Mirati Therapeutics (acquired by Bristol Myers Squibb), where he helped lead and set up the international foundations of the company and prepared multiple oncology launches.

Currently serves as a Board member at OncoInvent AS, a privately held clinical-stage radiopharmaceutical company, Oliveira obtained a degree in Pharmacy and a post-graduate degree in Drug and Pharmacy Law from the University of Coimbra, Portugal.

Source: BERNAMA News Agency